What DSIP actually is

Delta sleep-inducing peptide (DSIP) is a nine-amino-acid peptide isolated by Schoenenberger and colleagues at the University of Zürich in 1977 from cerebroventricular fluid of rabbits undergoing electrical sleep induction.¹

DSIP’s effects on sleep, opioid withdrawal, and stress response have been studied across decades. Modern peptide practice prescribes DSIP primarily for sleep architecture support — particularly delta-wave (slow-wave) sleep amplitude.²

At Luxbae, DSIP is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Delta-wave amplitude

Modulates GABAergic and opioidergic systems; documented effect on delta-wave amplitude in sleep EEG studies.¹

What the research shows

Slow-wave sleep. Increased delta-wave amplitude documented in EEG studies.¹

Sleep maintenance. Some patients report fewer nocturnal arousals.

Stress modulation. Documented dampening of HPA axis response in animal models.³

Side effects: Generally well-tolerated. Mild injection-site reactions, occasional vivid dreams.

FDA note: Not FDA-approved. Investigational; prescribed at Luxbae under medical supervision.

DSIP FAQ

Will I fall asleep faster?
DSIP affects sleep architecture more than sleep onset. Patients more often report deeper sleep than faster sleep.

Dependence risk?
No documented dependence pattern.

References

1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282-1286.
2. Pollard BJ, Pomfrett CJ. Delta sleep-inducing peptide. Eur J Anaesthesiol. 2001;18(7):419-422.
3. Bjartell A. Localization of delta sleep-inducing peptide-like immunoreactivity in human adrenal gland and small intestine. Neuroendocrinology. 1990.